Train the cell, then deploy: Science behind the new HIV study, and why it's a foothold, not a finish line

After decades of failed HIV vaccines, a new approach that predicts which cells to train, not just what antigen to show, has ...
manilatimes

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

TEL AVIV, Israel and BURLINGTON, Mass. , July 08, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics (Nasdaq: CMMB) ("Chemomab”) and Scipher Medicine Corporation ("Scipher”), a leader in transforming ...

Chemomab Therapeutics Ltd.: Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial ...

Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher's AI Network Medicine ...